.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Express Scripts
Julphar
Dow
Moodys
Chubb
McKesson
Queensland Health
Covington
Cantor Fitzgerald

Generated: December 18, 2017

DrugPatentWatch Database Preview

NEGGRAM Drug Profile

« Back to Dashboard

Which patents cover Neggram, and when can generic versions of Neggram launch?

Neggram is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in NEGGRAM is nalidixic acid. There are two drug master file entries for this compound. Additional details are available on the nalidixic acid profile page.
Drug patent expirations by year for NEGGRAM

Medical Subject Heading (MeSH) Categories for NEGGRAM

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsNEGGRAMnalidixic acidSUSPENSION;ORAL017430-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NEGGRAM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidSUSPENSION;ORAL017430-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidTABLET;ORAL014214-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsNEGGRAMnalidixic acidSUSPENSION;ORAL017430-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Express Scripts
UBS
Farmers Insurance
US Army
Deloitte
Medtronic
Queensland Health
Johnson and Johnson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot